Le Lézard
Classified in: Health
Subjects: BFA, CSR

Philadelphia To Demand Better For Patients At PurpleStride, The Walk To End Pancreatic Cancer


PHILADELPHIA, Oct. 17, 2017 /PRNewswire-USNewswire/ -- Thousands will run and walk to end pancreatic cancer, the world's toughest cancer, at PurpleStride Philadelphia on Saturday, Nov. 4 at Memorial Hall in Fairmount Park. The 10th annual event, presented by the Sidney Kimmel Cancer Center at Jefferson, is hosted by the Pancreatic Cancer Action Network (PanCAN) Philadelphia Affiliate.

The five-year survival rate for pancreatic cancer is just 9 percent. In order to save lives and double survival by 2020, PanCAN urges the greater Delaware Valley to join PurpleStride. Funds raised through the event support PanCAN's critical research, clinical initiatives and patient services, including Know Your Tumor®, Precision PromiseSM,  Clinical Trial Finder and the Patient Registry.

Antonella Arnone lost her husband Robert, a founding member of the Philadelphia Affiliate, to pancreatic cancer. She has made it her personal mission to improve patient outcomes.

"Our family continues Robert's legacy with Team Arnone at PurpleStride Philadelphia, allowing us to honor his memory and help make pancreatic cancer a thing of the past," said Arnone, whose team has raised nearly $20,000. "The money we raise funds research that could unlock the puzzle of pancreatic cancer. But unlocking the cure starts with us and we encourage more members of the community to participate and get involved."

The volunteer-led event is supported by national presenting sponsor Celgene, national gold sponsor AbbVie, gold sponsors Penn Pancreatic Cancer Research Center, IPSEN, Fox Chase Cancer Center, Drexel Cancer Care and gold media sponsor 6ABC. Meteorologist David Murphy from 6ABC will serve as event emcee. Opening ceremonies begin at 7:15 a.m., with a timed 5K run/walk beginning at 8 a.m.

To register, donate or learn more about PurpleStride Philadelphia, please visit purplestride.org/philadelphia. 

To learn more about the Pancreatic Cancer Action Network and its signature walk PurpleStride, watch the PurpleStride PSA and the organization's PSA. Follow PanCAN's Philadelphia affiliate on Facebook and Twitter. Follow PanCAN on TwitterInstagram and Facebook.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world's toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double survival by 2020.

Media Contacts:

Marisa Avallone Sharkey, APR
Media Relations Chair
Pancreatic Cancer Action Network ? Philadelphia Affiliate
(609) 203-1325; [email protected] 

Zahra Nealy, MA
Public Relations Specialist
Pancreatic Cancer Action Network
Direct: 310.706.3532 ; [email protected]

PurpleStride Philadelphia, the walk to end pancreatic cancer, is Nov. 4, 2017. Register or donate today at purplestride.org/philadelphia.

SOURCE Pancreatic Cancer Action Network


These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...



News published on and distributed by: